Additional InformationTHE PHARMACEUTICAL MARKET: PAKISTAN - REVIEW
The macroenvironmental indicators for the Pakistani pharmaceutical market are positive despite economic concerns. Economically, the Economist Intelligence Unit (EIU) projects that Pakistan will be the fourth smallest economy in the Asia Pacific region covered by Espicom in 2016. In GDP per capita terms, Pakistan will rank the second lowest in the Asia Pacific region in 2016. According to the EIU, Pakistan will remain heavily dependent on multilateral institutions and bilateral donors for concessional loans and emergency aid. Demographically, the EIU projects that Pakistan will have the fourth largest population in the Asia Pacific region by 2016. The elderly population represents a very small proportion of the population; it will be the lowest rate in the Asia Pacific region by 2016.
Intellectual property rights (IPR) continue to be a major concern amid patent issues and the prevalence of counterfeit drugs. Despite being a signatory to the WTO TRIPS agreement, Pakistan’s IPR protection for pharmaceuticals is very weak. Pakistan remains on the US Trade Representative’s (USTR) Priority Watch List in 2011. The USTR stated that Pakistan needs to improve the protection against unfair commercial use of pharmaceutical test data, and should establish an effective system to address the patent issues of pharmaceutical products. The Pakistan Medical Association alleges that nearly half of drugs available in the country are counterfeit and that the population spends around three-quarters of their household health budget on drugs, half of which may be fake or unfit for human consumption.
Pakistan’s pharmaceutical market is small and equally split between multinational and domestic companies. Espicom projects the market to grow at a fairly high single-digit CAGR in dollar terms during the forecast period. By 2016, it will be the 11th largest pharmaceutical market in the Asia Pacific region covered by Espicom. The pharmaceutical market in Pakistan is dominated by locally manufactured pharmaceuticals, predominantly generic drugs, which meet around 90% of country’s needs in 2011. Imported retail medicaments account for the remainder of the market, although manufacturers rely heavily on imported raw materials for production. Multinational companies account for around half of the market by value, although local producers have a far greater share in terms of volume.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
More Prescription Drugs reports by Espicom Healthcare Intelligence
Understanding the US's Regional Healthcare Markets by Espicom Healthcare Intelligence
Understanding the US's Regional Healthcare Markets
For years to come, the US healthcare market will remain the most attractive to providers of medical services. Considerable ...
The Pharmaceutical Market: Brazil by Espicom Healthcare Intelligence
The Pharmaceutical Market: Brazil
OVERVIEW OF THE PHARMACEUTICAL MARKET IN BRAZIL The Brazilian pharmaceutical market remains our favourite regional market in Latin America due to ...
Inhalation & Nasal Spray Generic Drugs 2013 by Espicom Healthcare Intelligence
Inhalation & Nasal Spray Generic Drugs 2013
Around three quarters of the US$36.4 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation ...
See all reports like this >>
Middle East North Africa Pharmaceutical Market Forecasts to 2018 by Espicom Healthcare Intelligence
Middle East North Africa Pharmaceutical Market Forecasts to 2018
The global pharmaceutical market is forecast to be worth over US$1,250 billion by 2018 - but ...
More Pakistan Prescription Drugs reports
Pakistan Pharmaceuticals and Healthcare Report Q3 2014 by Business Monitor International
Pakistan Pharmaceuticals and Healthcare Report Q3 2014BMI View: Pakistan remains one of the least attractive markets in the Asia Pacific region topharmaceutical and healthcare investment. ...
Pakistan Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: For new medicines to be launched into the Pakistani market, the pharmaceuticalregulator must drop its requirement for local rigorous drug approvals and registration ...
Antibiotics Market in Pakistan to 2016 by Global Research & Data Services
This market research report offers a perspective on the actual market situation, trends and future outlook for antibiotics in Pakistan. The study provides essential market ...
See all reports like this >>
Pakistan Pharmaceuticals and Healthcare Report Q4 2012 by Business Monitor International
BMI View: The operational environment for drugmakers in Pakistan has worsened over the past year, partly as a result of the dissolution of the Ministry ...
More Pakistan reports
D&B Country Report: Pakistan by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
See all reports like this >>
D&B Country RiskLine Report: Pakistan by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...